President Trump signed an executive order to reclassify marijuana from Schedule I to Schedule III, easing restrictions and potentially expanding medical access, while emphasizing it does not legalize recreational use. The move is seen as a significant shift in U.S. cannabis policy, opening doors for industry growth, research, and medical applications, with some stock impacts and industry implications.
Cannabis use among Americans aged 65 and older has increased by 46% between 2021 and 2023, with many seniors citing medicinal benefits, though health risks such as cardiovascular issues are a concern among medical professionals.
Many U.S. states have legalized cannabis, leading to increased use among older adults, according to family physician Jeffrey Quinlan, highlighting ongoing discussions about its health implications.
The Department of Health and Human Services released a 252-page review recommending the loosening of federal restrictions on marijuana, citing credible evidence of its medical benefits and lower potential for abuse compared to other scheduled drugs. This marks a significant departure from the federal government's longstanding classification of cannabis as a Schedule I drug. The review, conducted at the request of President Joe Biden, recommends moving marijuana to Schedule III, with the final decision resting with the Drug Enforcement Administration. The review also found that marijuana has a lower public health risk and potential for abuse than other scheduled drugs, based on scientific criteria and analysis of various medical conditions.
Federal scientists have recommended removing marijuana from the most restrictive category of drugs, citing its potential medical benefits and lower risk compared to other controlled substances. The 250-page scientific review, obtained through a lawsuit, suggests reclassifying marijuana as a Schedule III drug, based on findings that it has therapeutic uses for conditions like anorexia and pain, and does not produce serious outcomes compared to drugs in Schedules I or II. The recommendation is being considered by the Drug Enforcement Administration, with potential implications for federal drug policy and the marijuana industry.
A recent study highlights the potential health risks of cannabis use due to harmful fungi contamination, underscoring the need for more research and better regulations. The study calls for greater attention to fungal contaminants in cannabis and hemp, particularly for immunocompromised consumers, and suggests a two-tier system for medical and recreational products to ensure safety. The authors recommend further investigation and assessment of guidelines for the medical application of cannabis.
The viral trend of "Barbie Botox" has led to an increase in demand for toxin-based procedures among women in their 20s, aiming to mimic the appearance of Margot Robbie in the movie. However, doctors caution that this trend may lead to resistance among users and hinder medical use in the future. While the procedure has been used to treat migraines and shoulder pain, its cosmetic use is considered "off-label" as it is only approved for facial procedures. Concerns arise regarding the rise in use among younger women and the potential risks associated with underqualified staff performing the injections. Additionally, the repeated use of high amounts of Botox may lead to decreased effectiveness over time.
A study published in The Journal of the American Medical Association Network Open found that 21% of cannabis users struggle with cannabis use disorder, characterized by problematic use leading to impairment and distress. Of those, 6.5% had moderate to severe disorder. The study revealed that more severe dependency was associated with recreational use, while less severe but still problematic use was linked to both medical and recreational use. The most common symptoms reported were increased tolerance, craving, and uncontrolled escalation of cannabis use. The findings highlight the importance of assessing cannabis use and disorder symptoms in medical settings.
